Cell surface oligosaccharides have been shown to play essential biological roles in such diverse biological phenomena as cellular adhesion, molecular recognition, and inflammatory response. The development of high-affinity ligands capable of selectively recognizing a variety of small motifs in different oligosaccharides would be of significant interest as experimental and diagnostic tools. As a step toward this goal we have developed DNA ligands that recognize the disaccharide cellobiose, whether in soluble form or as the repeating unit of the polymer, cellulose. These DNA ''aptamers'' bind with high selectivity to cellobiose with little or no affinity for the related disaccharides lactose, maltose, and gentiobiose. Thus, the DNA ligands can discriminate sugar epimers, anomers, and disaccharide linkages.Oligosaccharide antigens play essential biological roles in cellular adhesion, molecular recognition, and inflammatory response. Classical carbohydrate binding macromolecules are proteins. These include plant and animal lectins (1-3) and anticarbohydrate antibodies raised in animals and humans (4). The ability to discriminate the presence of different saccharide types with relatively subtle structural differences would be of benefit in both experimental applications and diagnostics. Many routine clinical screens and research applications use immunological methods for which there are currently no antibodies that can discriminate among similar sugar linkages. Possible applications for selective, high-affinity ligands include Western blots, in situ staining, ''immuno'' precipitation, and various types of ''immuno'' affinity in microtiter format.High-affinity nucleic acid ligands, termed ''aptamers,'' can be selected from a random pool of nucleic acid sequences (refs. 5-12, reviewed in refs. 13-15). Aptamer selection is in theory much faster, cheaper, more versatile, and more reliable than antibody preparation. Such selection produces high-affinity ligands that can be propagated indefinitely with little risk of losing the stock, significantly lower cost than antibodies, and completely obviates the use of animals. In addition to possible ethical considerations, this also provides the opportunity to generate ligands to antigens that are toxic to humans and animals. The selection procedure, termed SELEX (systemic evolution of ligands by exponential enrichment, ref. 7) involves the iterative isolation of ligands out of the random sequence pool with affinity for a defined target molecule and PCR-based amplification of the selected RNA or DNA oligonucleotides after each round of isolation. This previously has been suggested as a route to drug discovery (7), with the possible use of nucleotide analogs to synthesize aptamers that are resistant to nucleolytic degradation (16). Targets for aptamer selection typically have been macromolecules with complex surfaces, but several cases of small molecule targets have been reported (17). Although SELEX has the potential to identify high-affinity ligands to a wide variety of...